Amicus Therapeutics, Inc. is a biotechnology company, which is engaged in the discovery, development and commercialization of novel treatments for patients living with rare and orphan diseases. Its product include migalastat HCl, which is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy for fabry disease. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ.

NPS Pharmaceuticals is an outsourcing-based development company focused on bringing biopharmaceuticals to patients with rare disorders and few, if any, therapeutic options. The company's lead clinical programs involve two proprietary therapeutic peptides to restore or replace biological function: Gattex® (teduglutide) and Natpara® (recombinant human parathyroid hormone (rhPTH 1-84)). NPS' earlier stage pipeline includes two calcilytic compounds, NPSP790 and NPSP795, with potential application in rare disorders involving increased calcium receptor activity, such as autosomal dominant hypocalcemia and hypercalciuria (ADHH). NPS complements its proprietary programs with a royalty-based portfolio of products and product candidates that includes agreements with Amgen, GlaxoSmithKline, Kyowa Hakko Kirin, Nycomed, and Ortho-McNeil Pharmaceuticals.

ViroPharma Incorporated is an international biopharmaceutical company committed to developing and commercializing innovative products that address unmet medical needs. We focus on providing products to physician specialists that support patients with serious diseases for which there is an unmet medical need, including disease caused by C1 esterase inhibitor deficiency and C. difficile. In everything we do, throughout our organization, we are committed to patient and physician needs, as we work to bring new products to markets with few, if any, therapeutic options. We are dedicated to transforming the promise of biotechnology into therapies that have the power to restore health and save lives.